Despite the introduction of protective measures, the COVID-19 pandemic has continued to take hold across the world. The latest data from the World Health Organisation indicates that over 40 million cases and 1.1 million deaths have been reported, with the spread of SARS-CoV-2 continuing to accelerate1.
Aside from the direct implications on individuals, their families, and our collective lifestyles, there are also profound indirect effects of rising infection rates. These include barriers to accessing essential healthcare, mental health impacts, limited social services, and an increase in the incidence of other diseases caused by pathogenic microorganisms2.
Legionella describes a group of pathogenic bacteria responsible for a potentially fatal pneumonia-like illness called Legionnaires disease. The bacteria are common in low numbers in freshwater environments. However, they can multiply in manmade water systems such as air conditioning cooling towers and humidifiers, leading to disease outbreaks in apartment buildings, hospitals, nursing homes, and other industrial buildings.
Measures used to reduce the spread of COVID-19 has the unfortunate effect of increasing the risk of legionnaires outbreaks. Local lockdowns and building closures result in water sources being left stagnant and warm, conditions in which the dangerous Legionella bacterium thrives3,4. Most recently, legionellae have been detected in buildings in Atlanta5, Montreal6, and Illinois7, posing a significant public health risk.
Clostridioides difficile (C. difficile) is a pathogenic bacterium found in the gut and can cause severe diarrhea and further intestinal complications. Infection is most common in people undergoing extended hospital stays and those taking certain broad-spectrum antibiotics8.
The association between C. difficile and antibiotic use results from disruption of the gut microbiome. The diversity of the intestinal microbial ecosystem is vital for protection against infection by pathogenic bacteria, and imbalances allow C. difficile to propagate in the gut of vulnerable individuals8.
Recent research suggests that around 70%0. of hospitalized COVID-19 patients were treated with antibiotics in an attempt to prevent co-infections and the spread of ‘superbugs’9, putting them at a greater risk of contracting C. difficile infections. A recent report identified nine patients with both COVID-19 and C. difficile infection at the Detroit Medical Center over six weeks during March/April10, indicating that such broad use of antibiotics could have significant consequences in healthcare settings.
Dengue fever is a tropical disease caused by the dengue virus and spread by mosquitos. It can be fatal and is, therefore, a serious concern in affected countries, primarily South and Southeast Asia and South America. The symptoms of dengue fever are similar to some of the symptoms of COVID-19, including fever, aches, and nausea11. Consequently, care must be taken to differentiate between these two diseases in dengue-endemic countries.
Misdiagnosis is linked to the similar clinical manifestations and pathophysiology of the diseases, as well as potential cross-reactivity between SARS‐CoV‐2 and dengue proteins, which impacts the specificity of blood tests12. Additionally, the co‐occurrence of COVID-19 and dengue represents a significant problem for healthcare resources in areas where dengue is endemic12. To help manage these challenges, the Delhi government has released guidelines for testing and treating both diseases during this incredibly challenging time13
Effective disease testing procedures are crucial for early detection, limiting transmission, and ensuring optimal treatment is provided. Novacyt offers effective testing solutions to help researchers and clinicians monitor various pathogens, particularly those linked to the COVID-19 pandemic.
To prevent outbreaks of Legionnaires disease, artificial water systems should be closely monitored for Legionella. This is particularly important before opening buildings that were unoccupied or under limited use during COVID-19 restrictions. Our PCR-based Legionella tests provide sensitivity and ease of use for the detection of these pathogens. Additionally, our immunoassay detects Legionella proteins in human urine to determine whether an individual has been infected and requires treatment.
Preventing the spread and effective treatment of C. difficile depends on rapid and accurate diagnosis14. Our simple antigen tests facilitate the detection of C. difficile from patient stool samples in less than ten minutes. Such efficient testing is essential in COVID-19 patients in hospital settings, where the risk of C. difficile co-infections is increased.
Finally, testing allows healthcare providers to differentiate between diseases with similar symptoms, such as dengue fever and COVID-19. We offer highly sensitive PCR tests to detect dengue and produce a simple multiplexing kit that can distinguish between dengue subtypes.
References
